NextCure, Inc.
NXTCAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jul 15, 2026 | H.C. Wainwright | Emily Bodnar | $20.00(+204%) | $6.58 | StreetInsider |
| Jul 15, 2025 | Piper Sandler | Edward Tenthoff | $15.00(+215%) | $4.76 | TheFly |
| Jun 3, 2024 | Piper Sandler | Edward Tenthoff | $3.00(+97%) | $1.52 | StreetInsider |
| Nov 3, 2022 | Piper Sandler | Edward Tenthoff | $6.00(+139%) | $2.51 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Ladenburg Thalmann | upgrade | Neutral →Buy | Nov 7, 2025 |
| Piper Sandler | maintain | Overweight | Jul 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jul 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 17, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 11, 2024 |
| Needham | maintain | Buy | Aug 2, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 31, 2024 |
| Needham | maintain | Buy | May 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 22, 2024 |
| Needham | maintain | Buy | Mar 20, 2024 |
| Needham | maintain | Buy | Dec 14, 2023 |
| Needham | maintain | Buy | Aug 4, 2023 |
| Needham | maintain | Buy | May 5, 2023 |
| Needham | maintain | Buy | Mar 3, 2023 |
| Piper Sandler | maintain | Overweight | Nov 4, 2022 |
| Ladenburg Thalmann | downgrade | Buy →Neutral | Nov 4, 2022 |
| Needham | maintain | Buy | Nov 4, 2022 |
| Truist Securities | maintain | Buy | Aug 23, 2022 |
| Piper Sandler | maintain | Overweight | May 23, 2022 |
| Ladenburg Thalmann | maintain | Buy | Mar 1, 2022 |
| Needham | maintain | Buy | Nov 5, 2021 |
| Truist Securities | upgrade | Hold →Buy | Mar 5, 2021 |
Earnings History
Next report: Mar 4, 2027 · EPS est. $-0.79| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-2.80 | $-1.95 | — | — |
| May 7, 2026 | $-1.87 | $-1.81 | — | — |
| Mar 5, 2026 | $-0.81 | $-2.26 | — | — |
| Nov 5, 2025 | $-3.22 | $-4.06 | — | — |
| Aug 7, 2025 | $-11.29 | $-4.62 | — | — |
| May 1, 2025 | $-4.68 | $-4.80 | — | — |
| Mar 6, 2025 | $-4.92 | $-0.35 | — | — |
| Nov 7, 2024 | $-4.92 | $-0.38 | — | — |
News
NextCure, Inc. (NASDAQ: NXTC - Get Free Report)'s stock price was up 7.7% during trading on Tuesday. The company traded as high as $8.64 and last traded at $8.42. 95,035 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 147,812 shares. The stock had previously closed at $7.82.
Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001 Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029 SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Avere Therapeutics, Inc. ("Avere" or the "Company"), a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, today ann…